Yunhong Huang

机构：Guiyang Medical University, Guizhou Cancer Hospital, Affiliated Hospital of Guizhou Medical University · ORCID：0000-0003-2436-6202

发表论文 57 篇 · 总被引 351 次 · h-index 12

代表论文

• Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study (2023 · Journal of Clinical Oncology · 被引 51)
• Factors associated with progression of different prediabetic status to Diabetes: A Community-based cohort study (2022 · Diabetes Research and Clinical Practice · 被引 18)
• Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas (2022 · Blood · 被引 12)
• Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial (2025 · Cancer · 被引 11)
• Serum spexin differed in newly diagnosed type 2 diabetes patients according to body mass index and increased with the improvement of metabolic status (2022 · Frontiers in Endocrinology · 被引 11)
• Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ® ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial (2022 · Hematological Oncology · 被引 9)